[8]. He X, et al. Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma. J Immunother Cancer. 2020;8(2):e000807. [9]. Zhou C, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy...
肺癌是最为常见的、致死的一类癌症,每年约有160万人死于肺癌,约85%在组织学分型上属于NSCLC,其中主要为肺腺癌(lung adenocarcinoma, LUAD)和肺鳞癌(lung squamous cell carcinoma, LUSC)。与小细胞肺癌(small cell lung cancer, SCLC...
Squamous cell carcinomaTargeted therapiesGenetic alterationsTailored treatmentLung cancer is the leading cause of cancer-related death worldwide, and squamous cell carcinoma is the second most frequent histological subtype. The improvement registered in the last years in the treatment of non-small cell ...
Non–small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Histologically, NSCLC is divided into adenocarcinoma, squamous cell carcinoma (SCC) (see the image below), and large cell carcinoma. [1] Patients with NSCLC require a complete staging workup to evaluate the...
[8]. He X, et al. Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma. J Immunother Cancer. 2020;8(2):e000807. [9]. Zhou C, et al. Camrelizumab plu...
2.Campbell JD,Alexandrov A,Kim J,et al.Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas[J].Nat Genet,2016,48(6):607-16. 3.Gao W,Jin J,Yin J,et al.KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients[J].Mol...
squamous cell carcinomaDysregulation of microRNAs is a common mechanism in the development of lung cancer, but the relationship between microRNAs and expression subtypes in non‐small‐cell lung cancer (NSCLC) is poorly explored. Here, we analyzed microRNA expression from 241 NSCLC samples and ...
[12] Byhardt RW, et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung[J]. Int J Radiat Oncol Biol Phys. 1998;42...
Carcinoma, Non-Small-Cell LungCarcinoma, Squamous CellLung NeoplasmsQuinazolinesReceptor, Epidermal Growth FactorProtein Kinase InhibitorsTreatment OutcomeOn April 16, 2010, the U. S. Food and Drug Administration (FDA) approved erlotinib tablets (Tarceva庐; OSI Pharmaceuticals, Inc., Melville, NY) ...
transformation to small-cell lung cancer (SCLC), epithelial-mesenchymal transition (EMT), the conversion to squamous cell carcinoma (SCC), activation of the Wnt/β-catenin pathway, hormonal signaling, and cell cycle were observed in someEGFRmutant cases compared to wild-type EGFR cases [22,23,...